MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients
Clinical trial NCT02213744 · TERMINATED
Trial details
- NCT number
- NCT02213744
- Sponsor
- Merrimack Pharmaceuticals
- Status
- TERMINATED
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2014-07-01
- Primary completion
- 2016-12-01
- Enrollment
- 113
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.